Brett Collins is an NHMRC Career Development Fellow and head of the Molecular Trafficking Lab at UQ's Institute for Molecular Bioscience. He was a lead investigator in the seminal structural studies of AP2, the protein adaptor molecule central to clathrin-mediated endocytosis, and has since defined the molecular basis for the function of critical proteins regulating membrane trafficking and signalling at the endosome organelle. His team is now focused on understanding how discrete molecular interactions between proteins and lipids control these processes in human cells.

Associate Professor Collins was awarded his PhD in 2001 and has published over 75 papers including in Cell, Nature, Nature Structural and Molecular Biology, Developmental Cell, and The Proceedings of the National Academy of Sciences USA, altogether cited more than 3100 times. He is the recipient of 3 prestigious fellowships, including a previous Career Development Award from the National Health and Medical Research Council and a Future Fellowship from the Australian Research Council, and was awarded the University of Queensland Research Excellence Award in 2008. In 2015 he was awarded the Emerging Leader Award of the ANZSCDB and in 2016 the Merck Research Medal from the ASBMB. He is currently the President of the Queensland Protein Group.

Dr. Larisa Labzin studies how our innate immune system detects viral infections and how it decodes different signals to mount an appropriate immune response. Dr. Labzin's interest in innate immunity started during her honours training with Prof. Matt Sweet at the IMB, looking at how inflammatory signalling is regulated in macrophages. After gaining more experience while working as a research assistant for Prof. Sweet, she moved to Germany to the University of Bonn for her PhD. At the Univeristy of Bonn, Dr. Labzin investigated the anti-inflammatory effects of High-Density Lipoprotein with Prof. Eicke Latz. Here she discovered novel regulatory pathways that control inflammation. Dr. Labzin then moved to Cambridge, UK as an EMBO postdoctoral fellow to work with Dr. Leo James at the Medical Research Council Laboratory for Molecular Biology. In Dr. James' lab Dr. Labzin focused on how viruses are sensed by the innate immune system to trigger inflammation. In particular, Dr Labzin investigated how antibodies change the way viruses trigger inflammation. While in Cambridge, Dr. Labzin was awarded an NHMRC CJ Martin Fellowship to return to Australia. Larisa returned to the IMB in September 2019 to work with Prof. Kate Schroder. Dr. Labzin is an IMB Fellow and leads an independent research team studying inflammation in response to influenza and SARS-CoV-2.

Kindly visit my laboratory's webpage for more information

Overview

Professor Michael O'Sullivan is a neuroscientist, neurologist and group leader at the Institute for Molecular Bioscience (IMB). His main research interest is the neurobiology of brain injury, with an emphasis on mechanisms of resilience and recovery of the brain after injury. His previous work has developed understanding in two broad areas:

• The cognitive neuroscience of memory and cognitive control – and how distributed and dynamic networks in the brain support these functions, which are often affected by injury.
• How injury alters network structure and function leading to symptoms in day-to-day life - and intrinsic mechanisms of neural adaptation that modulate the effect of injury

At the Institute for Molecular Bioscience, O'Sullivan is building a research program on cellular and molecular events that influence adaptation and recovery, including the role of innate immunity and glial cells. This program includes novel approaches to neuroprotection and the role of astrocytes as key regulators of glutamate and neuroinflammation. A major theme is identification of therapeutic targets, and evaluation of disease progression or treatment response in vivo, using advanced human imaging with MRI, PET and novel radiotracers. In addition to his Institute work, O'Sullivan leads clinical and biomarker projects in stroke and traumatic brain injury and is a member of the NHMRC Centre for Research Excellence in vascular mechanisms of cognitive impairment.

The group is at the forefront in the application of advanced techniques to investigate brain structure and function in vivo, including diffusion MRI and tractography, the use of functional MRI and EEG to examine to examine dynamic network interactions, and PET to examine neurochemistry.

Supervision

Professor O'Sullivan supervises PhD projects across multiple research areas, including clinical science, cognitive neuroscience, animal models and computational neuroscience (such as machine learning and deep learning algorithms for diagnosis and prediction of prognosis). Expressions of interest from potential PhD and honours students are welcome.

Career Summary: 2009: PhD, University of Michigan, USA with training in cardiac physiology, modelling myocardial ischemia in vivo and in vitro, and development of therapeutic approaches for myocardial ischemia; 2009–2015: Postdoctoral Research Fellow, University of Washington, Institute for Stem Cell and Regenerative Medicine, USA with training in stem cell biology, genomics, genome editing, and cell therapeutics for ischemic heart disease; 2015–current: Group Leader, University of Queensland (UQ), Institute for Molecular Bioscience; 2022-current: Associate Professor, UQ; 2018–2021 and 2023-2026: National Heart Foundation Future Leader Fellow. Dr. Palpant's research team has expertise in human stem cell biology, computational genomics, and cardiac physiology, which enables them to translate outcomes from cell biology and genomics to disease modelling, drug discovery, and preclinical modelling.

Our research focuses on understanding how cells work and what goes wrong in disease. We are studying the role of cellular organelles in defence against pathogens, the molecular changes underlying muscle disease, and optimising methods to deliver therapeutics to specific cell types in whole animals.

Professor Robert Parton is an ARC Laureate Fellow, a group leader in the IMB Centre for Cell Biology of Chronic Disease, and Deputy Director of the Centre for Microscopy and Microanalysis. He is a Fellow of the Australian Academy of Science and an Associate Member of EMBO.

Professor Kate Schroder heads the Inflammasome Laboratory and is Director of the Centre for Inflammation and Disease Research at the Institute for Molecular Bioscience (IMB), University of Queensland, as an NHMRC Leadership Fellow. Kate's graduate studies defined novel macrophage activation mechanisms and her subsequent postdoctoral research identified surprising inter-species divergence in the inflammatory programs of human versus mouse macrophages. As an NHMRC CJ Martin Fellow in Switzerland, Kate trained with the pioneer of inflammasome biology, Jürg Tschopp. The IMB Inflammasome Laboratory, which Kate heads, investigates the molecular mechanisms governing inflammasome activity and caspase activation, the cellular mediators of inflammasome-dependent inflammation, and mechanisms of inflammasome inhibition by cellular pathways and small molecule inhibitors.

Kate is a co-inventor on patents for small molecule inhibitors of the NLRP3 inflammasome, currently under commercialisation by Inflazome Ltd. Inflazome Ltd was recently acquired by Roche in a landmark deal – one of the largest in Australian and Irish biotech history. The acquisition gives Roche full rights to Inflazome's portfolio of inflammasome inhibitors. Two of the company's drug candidates are in clinical trials for the treatment of debilitating conditions such as cardiovascular disease, arthritis and neurodegenerative diseases such as Parkinson's, Alzheimer's and motor neuron disease.

Kate has authored more than 140 publications, featuring in journals such as Science, Cell, Nature Genetics, Nature Medicine, Nature Chemical Biology, Journal of Experimental Medicine and PNAS USA, and her work has been cited more than 35,000 times. Kate is an Editorial Board Member for international journals including Science Signaling, Clinical and Translational Immunology and Cell Death Disease. She is the recipient of the 2022 Women in Technology Excellence in Science Award, 2020 Nancy Mills Award for Women in Science, 2019 ANZSCDB Emerging Leader Award, 2019 Merck Research Medal, 2014 Milstein Young Investigator Award, 2013 Tall Poppy Award, 2012 Gordon Ada Career Award, 2010 QLD Premier's Postdoctoral Award, and the 2008 Society for Leukocyte Biology's Dolph Adams Award.

INFLAMMASOME LABORATORY RESEARCH

During injury or infection, our body's immune system protects us by launching inflammation. But uncontrolled inflammation drives diseases such as gout, diabetes, neurodegenerative disease and cancer. The Inflammasome Lab is defining the molecular and cellular processes of inflammation. We seek to unravel the secrets of inflammasomes – protein complexes at the heart of inflammation and disease – to allow for new therapies to fight human diseases.

The Inflammasome Laboratory integrates molecular and cell biology approaches with in vivo studies to gain a holistic understanding of inflammasome function during infection, and inflammasome dysfunction in human inflammatory disease. Current research interests include the molecular mechanisms governing inflammasome activity and caspase activation, the cellular mediators of inflammasome-dependent inflammation, and inflammasome suppression by autophagy and small molecule inhibitors.

Dr Stehbens is a cell biologist with a long-standing interest in understanding the fundamental mechanisms that regulate cell adhesion and the cytoskeleton. She has made key contributions to the fields of quantitative microscopy, cell motility, adhesion and the cytoskeleton with publications spanning multiple fields from ion channels in brain cancer, to growth factor signalling and autophagy. Her research group (joint between AIBN and IMB) aims to understand the fundamental principles of how cells integrate secreted and biomechanical signals from their local microenvironment to facilitate movement and survival. They have uncovered an entirely novel role for the microtubule cytoskeleton in protecting cells from cortical and nuclear rupture during cell migration in 3D cell migration and invasion. Using patient-derived tumour cells, coupled to genetic alteration and substrate microfabrication, they use state-of-the-art microscopy to understand the mechanisms of cell migratory behaviour required for cancer cells to traverse the body during metastasis.

Her graduate work in the laboratory of Alpha Yap (IMB IQ) discovered how the microtubule cytoskeleton regulates cell-cell adhesion. After which she relocated to The University of California San Francisco (UCSF) to work with Prof Wittmann, a microtubule biologist who is an expert in live-cell spinning disc microscopy. Here she worked at the cutting edge of biology imaging advancements as the greater bay area research community combines several of the top-laboratories for imaging technologies. Supported by a competitive American Heart Fellowship Post-Doctoral fellowship, she identified how microtubules coordinate protease secretion during migration to mediate cell-matrix adhesion disassembly. In 2013, she returned to Australia to expand her imaging-based skill set to focus on models of cancer cell biology. Working with Prof. Pamela Pollock (QUT) she uncovered how activating FGFR2 mutations resulted in a loss of cell polarity potentiating migration and invasion in endometrial cancer. Following this, she worked with Prof. Nikolas Haass (UQDI) a melanoma expert, investigating the role of microtubule +TIP proteins in 3D models of metastatic invasion before starting her lab at the Institute for Molecular Bioscience as an ARC Future Fellow.

Lab Overview

Cells in living organisms navigate highly crowded three-dimensional environments, where their coordinated migration provides the driving force behind developmental and homeostatic tissue maintenance. Our research aims to understand the fundamental principles underpinning how cells integrate secreted and biomechanical signals from their local microenvironment to facilitate cell movement and survival. We apply these findings to understand how cancer cells exploit this to metastasise or spread to distal tissues. We hypothesise that targeting the crosstalk between the cytoskeleton and the mechanical micro-environment, can be developed as an anti-metastatic approach.

Cancer cells spread aggressively through tissues by adapting their cell shape to fit the environment in addition to altering their environment so they can squeeze through tight tissue spaces. Cancer cells sense and become more invasive following changes in the biophysical properties their microenvironment including increases in stromal stiffness and interstitial fluid pressures. These changes make cancer cells mechanically compliant and adaptive to fluctuations in their surrounding environment allowing them to alter their shape to fit matrix physical attributes. As such, cells need mechanisms in place to 1) detect these physical limits, 2) deform their cortex whilst producing mechanical force for forward locomotion and 3) orient themselves to move through tissues. We focus on understanding- at the molecular level- how the microtubule cytoskeleton and microtubule associated proteins called +TIPs, regulate how cells move through physically challenging environments. To do this we utilize cutting-edge methodology including microchannel fabrication, novel light sheet microscopy, quantitative imaging methods in combination with patient-derived cell and 3D hydrogel models to recapitulate the 3D microenvironment.

Our research areas include:

• Cytoskeleton
• Cell adhesion
• Cell migration
• Cell mechanics
• Cancer cell biology

Areas of Expertise

Microtubules and Cell-Cell Adhesion

My early research, in the laboratory of Professor Alpha Yap, focused on understanding how the microtubule cytoskeleton regulates E-cadherin-based cell-cell adhesion. This work was the first to discover that it was the dynamacity, not simply the tethering, of the microtubule cytoskeleton that was critical for E-cadherin accumulation and junctional reinforcement. This was in addition to defining a previously unappreciated role for the cytokinetic machinery (Ect2) in regulating cell-cell adhesion

• Stehbens, S.J., …,and Yap, A. S. (2006). Dynamic Microtubules Regulate the Local Concentration of E-cadherin at Cell-Cell Contacts. Journal of Cell Science 119: 1801-1811
• Ratheesh, A., … Stehbens, S.J., and Yap, A.S. (2012). Centralspindlin and α-catenin regulate Rho signalling at the epithelial zonula adherens. Nature Cell Biology 14(8): 818-28

Microtubules and Cell-Matrix Adhesion

Following my PhD, I relocated to the University of California San Francisco to work with Professor Torsten Wittmann, an expert in live-cell spinning disc microscopy and microtubule functions during cell motility. This work was dogma changing and established how the microtubule interacting protein, CLASP, facilitates targeted protease secretion at focal adhesions during epithelial sheet migration to mediate cell-matrix adhesion disassembly, from the inside-out. It includes the first observation of live, directed exocytosis of the matrix protease MT1MMP at focal adhesions. Our work pioneered the combined application of quantitative live-cell protein dynamics and the application of the novel super resolution imaging technique, SAIM (Scanning Angle Interference Microscopy). During my time at UCSF I learnt how to custom design live-cell microscopes with these live-cell imaging platforms now commercially distributed as the Spectral Diskovery and Andor Dragonfly.

• Stehbens, S.J., … and Wittmann., T (2014). CLASPs link focal-adhesion-associated microtubule capture to localized exocytosis and adhesion site turnover. Nature Cell Biology 16(6): 558-570
• Stehbens, S.J., and Witmann, T. (2014) Analysis of focal adhesion turnover: a quantitative live-cell imaging example. Methods in Cell Biology 123: 335-46
• Stehbens, S.J., and Witmann, T. (2012) Targeting and transport: how microtubules control focal adhesion dynamics. Journal of Cell Biology 20, 198(4): 481-9

Cell Morphology and Cancer Biology

In 2013 I returned to Australia, joining the lab of Pamela Pollock with focus on applying my skill set to have translational impact. Here I described the impact of activating FGFR2b-mutations on endometrial cancer progession. These findings uncovered collective cell polarity and invasion as common targets of disease-associated FGFR2 mutations that lead to shorter survival in endometrial cancer patients.

Stehbens, S.J, Ju, R.J and Pollock P.M. (2018) FGFR2b activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer. Journal of Cell Science, 131(15)

Microtubules in Metastatic Plasticity

In 2017, I joined the Experimental Melanoma Group at UQDI, where I work together with Professor Nikolas Haass in applying innovative live-cell spinning disc confocal imaging and biosensor approaches to understand cell-cell and cell-matrix interactions of melanoma with its microenvironment. Our work explores the adaptive role that the microtubule cytoskeleton plays in facilitating cell shape plasticity, matrix remodelling and resistance to compression during migration in complex 3D matrix models of metastatic melanoma invasion. We are fundamentally interested in understanding the reciprocal biophysical relationship between the microtubule cytoskeleton and the microenvironment during melanoma invasion, with the aim to expand our findings to other metastatic cancers.

Ju, Robert J., Stehbens, Samantha J., Haass, Nikolas K. 2018, 'The Role of Melanoma Cell-Stroma Interaction in Cell Motility, Invasion, and Metastasis', Frontiers in Medicine, vol. 5

Professor Jennifer Stow is a molecular cell biologist, an NHMRC Leadership Fellow and head of the Protein Trafficking and Inflammation research laboratory in The University of Queensland's Institute of Molecular Bioscience (IMB). Her previous leadership appointments include as Division Head and Deputy Director (Research) at IMB (12 years) and she currently serves on national and international advisory boards, editorial boards and steering committees, and as an elected Associate Member of the European Molecular Biology Organisation (EMBO).

Jenny Stow received her undergraduate and PhD qualifications at Melbourne's Monash University before undertaking postdoctoral training in the Department of Cell Biology at Yale University School of Medicine, USA. With training as a microscopist in kidney research, she gained further experience at Yale as a postdoc in the lab of eminent cell biologist and microscopist, Dr Marilyn Farquhar, where protein trafficking was both a theme and a passion. Jenny then took up her first faculty appointment as an Assistant Professor in the Renal Unit at Massachusetts General Hospital (MGH) and Harvard Medical School in Boston USA, where her research uncovered new roles for a class of enzymes, GTPases, in regulating trafficking within cells. At MGH her research also formed part of a highly successful NIH Renal Cell Biology Program. In late 1994, Jenny moved her research lab back to Australia, to The University of Queensland, in late 1994 as a Wellcome Trust International Medical Research Fellow. As part of IMB since, the Stow lab has continued a focus on protein trafficking, including pioneering live-cell imaging, to spearhead their work on trafficking in inflammation, cancer and chronic disease. Major discoveries include identifying new proteins and pathways for recycling adhesion proteins in epithelial cells, inflammatory cytokine secretion in macrophages and immune signalling through Toll-like receptors in inflammation and infection. Small GTPases of the Rab family, signalling adaptors and kinases feature among the molecules studied in the Stow lab for their functional roles and their potential as drug targets in inflammation and cancer. A keen focus is to understand the role of the fluid uptake pathway, macropinocytosis, in controlling inflammation, cancer and mucosal absorption.

Professor Stow has been awarded multiple career fellowships including from American Heart Association, Wellcome Trust and NHMRC. She has published >200 papers, cited over 15,500 times and she is the recipient of awards and honours, most recently including the 2019 President's Medal from the Australia and New Zealand Society for Cell and Developmental Biology. She is also academic head of IMB Microscopy, a world-class fluorescence microscopy and image analysis facility. Her research is funded by a variety of agencies and industry partnerships, in addition to NHMRC and ARC, including through the ARC Centre of Excellence in Quantum Biotechnology, QUBIC. The Stow lab work with national and international collaborators and welcome students and postdoctoral trainees to participate in their research. We value having a diverse, inclusive and supportive culture for research and celebrate the many diverse and wonderful successes of Stow lab alumni.

Matt Sweet is an NHMRC Leadership Fellow, Group Leader, and Director of Higher Degree Research (DHDR) at the Institute for Molecular Bioscience (IMB) at The University of Queensland, Brisbane, Australia. He was the founding Director of the IMB Centre for Inflammation and Disease Research (2014-2018), also serving as Deputy Head of the IMB Division of Cell Biology and Molecular Medicine during this period. Matt studies innate immunity, the body's danger sensing system that responds to infection, injury and dysregulated homeostasis, and the role of this system in health and disease. Matt's research team focuses on manipulating the innate immune system for the development of anti-infective and anti-inflammatory strategies. To do so, his lab characterizes the roles of specific innate immune pattern recognition receptors and their downstream signalling pathways/gene products in inflammatory disease processes, as well as in host responses to bacterial pathogens. He has authored >175 journal articles and book chapters, including in Science (2), Science Translational Medicine, Science Immunology, Nature Immunology, Nature Genetics, Nature Communications (4), PNAS USA (6) and Journal of Experimental Medicine (2), and his career publications have accrued >19,000 citations.

Biography

I was awarded a PhD (The University of Queensland) in 1996 for my research under the supervision of Prof David Hume into gene regulation in macrophages, immune cells with important roles in health and disease. I subsequently undertook a short postdoctoral position in the same laboratory, focusing on the activation of macrophages by pathogen products. I then embarked on a CJ Martin post-doctoral training fellowship with Prof Eddy Liew, FRS at the University of Glasgow in Scotland. Returning to The University of Queensland, I had a prominent role within the Cooperative Research Centre for Chronic Inflammatory Diseases (including as UQ node head from 2007-2008) and was appointed as a Group Leader at the IMB in 2007. I have continued fellowship support since this time, including as an ARC Future Fellow, an NHMRC Senior Research Fellow and an NHMRC Leadership Fellow (current, from 2021).

Key discoveries

CpG-containing DNA as an activator of innate immunity, and characterization of the receptor (TLR9) detecting this microbial component.

The IL-1 receptor family member ST2 as a critical regulator of innate immunity and inflammation.

Inflammatory and antimicrobial functions of histone deacetylase enzymes (HDACs) in macrophages.

Effects of the growth factor CSF-1 on inflammatory responses in macrophages.

Mechanisms responsible for divergence in TLR responses between human and mouse macrophages, as well as the functional consequences of such divergence.

TLR-inducible zinc toxicity as an antimicrobial weapon of macrophages and the identification of defects in this pathway in cystic fibrosis.

Host evasion strategies used by the bacterial pathogens Salmonella enterica serovar Typhimurium and uropathogenic E. coli.

SCIMP as a novel TLR adaptor that mediates TLR tyrosine phosphorylation and selective cytokine outputs.

Genes and pathways associated with the severity of chronic liver disease.

Molecular mechanisms controlling macrophage immunometabolism, as well as associated inflammatory and antimicrobial responses.

Anti-inflammatory and antibacterial activities of the metabolite ribulose-5-phosphate.

Research training

I have supervised or co-supervised 29 completed PhD students and 22 completed honours students, as well as 9 post-doctoral researchers. Many of my former staff and students continue to have active research careers around the world (USA, UK, Europe, Australia), including as independent laboratory heads. I currently supervise 5 PhD students in my laboratory, co-supervise 4 PhD students in other laboratories, and oversee the research activities of 2 post-doctoral researchers in my group. Current and former staff/students have received numerous fellowships and awards during their research careers (e.g. ARC DECRA, NHMRC CJ Martin fellowship, UQ post-doctoral fellowship, Smart State scholarship). I have also examined >25 PhD theses in the fields of innate immunity, inflammation and host defence.

Professional activities

I am an editorial board member of the Journal of Leukocyte Biology and Seminars in Cell & Developmental Biology, and have served as an editorial board member for several other journals in the past e.g. Immunology and Cell Biology. I have served on NHMRC project grant review panels in 2007, 2008, 2009, 2012 (as panel chair) and 2014, NHMRC Ideas panels in 2020 and 2024, NHMRC Investigator panels in 2021 and 2022, as well as a member of the NHMRC RGMS user reference group committee from 2010-2012. I acted as national representative for the Australasian Society of Immunology (ASI) Infection and Immunity special interest group from 2012-2017. At UQ, I served as chair of an animal ethics committee from 2013-2014, and co-organized the UQ Host-Pathogen interaction network from 2007-2010 (prior to the establishment of the Australian Infectious Diseases Research Centre). I am currently Director of Higher Degree by Research at IMB, overseeing HDR student recruitment and training.

I have made extensive contributions to conference organization in my discipline. I co-organized the national TLROZ2009 and TLROZ2012 conferences, I organized the first ever Australasian Society for Immunology (ASI) Infection and Immunity workshop (2009), was chair of the ASI Program Committee and co-organizer of the Infection and Immunity workshop for ASI2017, and I co-organized the annual IMB Inflammation Symposium (2014-2018). I also co-chaired the 2019 World Conference of Inflammation (Sydney, September 2019). In addition, I have been a member of the organizing committee for ASI2009, the 2014 International Cytokine and Interferon Society conference, the Lorne Infection and Immunity conference (2014-2020), and the Brisbane Immunology Group annual meeting (2008 to the present).

Dr Melanie White heads the Dynamics of Morphogenesis Lab at the Institute for Molecular Bioscience (IMB), University of Queensland and is an ARC Future Fellow. She completed a PhD in Neuroscience at University College London followed by postdoctoral research at The University of Edinburgh. During this time Mel engineered viruses to modulate gene expression in the brain to investigate neuronal function and as a therapeutic approach for neurodegenerative disease. Her work was published in Neuron and PNAS, featured in Nature Reviews Neuroscience and received extensive international media coverage (including the BBC and The Guardian).

In 2012 Mel switched fields to apply quantitative imaging in developmental biology. Her work revealed key mechanisms driving the earliest morphogenetic events in mammalian embryogenesis and was published in Cell, Science, Nature Cell Biology, Developmental Cell and Nature Protocols. Her research was featured on the cover of multiple journals including Cell and she was awarded the inaugural American Society for Cell Biology Porter Prize for Research Excellence (2018).

In 2020, Mel joined the IMB where she will combine her passion for neuroscience and developmental biology to investigate the dynamics of neural tube morphogenesis.

Research overview

The brain and the spinal cord control most of the functions of the body and the mind, yet the dynamics of how they first form is poorly understood. Both structures arise from a common precursor, the neural tube, which forms very early in embryonic development. To generate the forces that sculpt and shape the neural tube, changes in cellular architecture must be tightly coordinated in space and time. These morphological rearrangements occur concurrently with biochemical signalling pathways that specify early neural cell fates.

Our research aims to understand how cellular properties and transcriptional regulators interact with mechanical forces in real time to direct vertebrate neural tube formation and neural cell fate specification. We study the dynamics of neural tube formation by applying advanced imaging technologies in transgenic avian models and human stem cell models.

My group studies the role of cadherin cell adhesion molecules in morphogenesis and tumor development. E-cadherin is a key mediator of cell-cell recognition. It participates in tissue patterning and its dysfunction contributes to tumor progression and invasion.

Associate Professor Yap is the group leader for Cadherin cell adhesion molecules, Epithelial morphogenesis & Cell locomotion research at the IMB.

Professor Mark Schembri is a prominent microbiologist with experience in combating the global health crisis presented by multi-drug resistant pathogens. Professor Schembri's expertise on the virulence of bacterial pathogens and his innovative analysis of biofilm formation aims to improve the outcomes of the >400 million individuals that suffer from urinary tract infections each year across the globe.

Through the application of genetic, genomic and functional studies on uropathogenic E. coli, Professor Schembri has identified targets to reduce the virulence of this pathogen, and will pursue the development of life-saving therapeutic and preventative advances with the assistance of NHMRC, MRFF and ARC grants. Professor Schembri has tracked the rapid emergence and global spread of a virulent, drug-resistant E. coli clone and used genome sequencing to understand its evolution and virulence.

Links: Professor Schembri collaborates with national and international research leaders, including in Denmark, where he was a lecturer. Professor Schembri has strong links with other international experts in his field, including at the Pasteur Institute and the Wellcome Trust Sanger Institute in Cambridge. His research collaborations also span lead groups at UQ and other top Australian institutes, including Griffith and La Trobe Universities.

Membership, Funding and patents: Since 2014, Professor Schembri has been awarded over $15 million in funding from competitive national research funding bodies. He holds provisional patents for the development of novel therapeutic agents and vaccine antigens. He is a Fellow of the American Academy of Microbiology, and is regularly invited to speak at international conferences in his field.

Awards and Communication: Professor Schembri was the recipient of the Frank Fenner Award (2010) and the ASM BacPath Oration Award (2019) for his outstanding original research contribution to the study of Infectious Disease. He was an Australian Research Council Future Fellow (2011-2015) a National Health and Medical Research Council Senior Research Fellow (2016-2020). Professor Schembri is the author of >240 peer-reviewed research manuscripts. He is President of the Australian Society for Microbiology (2022-2026).

Professor Mark Blaskovich is an antibiotic hunter and Director of Translation at the Institute for Molecular Bioscience at The University of Queensland. He is co-founder and former Director of the Centre for Superbug Solutions at IMB.

A medicinal chemist with 15 years of industrial drug development experience prior to his academic career, Mark has been developing new antibiotics to treat drug resistant pathogens and using modified antibiotics to detect bacterial infections. He is a co-founder of the Community for Open Antimicrobial Drug Discovery, a global antibiotic discovery initiative, and has led a number of UQ-industry collaborations focused on antibiotic development. An inventor on eleven patent families, Mark has developed drugs in clinical trials, published more than eighty research articles, and received over $10m in grant funding.

Professor Denise Doolan is Director of Research at the Institute for Molecular Bioscience. She joined IMB in 2022 and was previously Deputy Director of the Australian Institute of Tropical Health and Medicine, and Director of the JCU Centre for Molecular Therapeutics, at James Cook University.

She is a molecular immunologist, working on the development of vaccines, diagnostics and host-directed therapeutics for infectious and chronic diseases that impact global public health, with a particular focus on malaria. Her cross-disciplinary research program spans host-pathogen immunity, antigen discovery, vaccine engineering, and biomarker discovery. A particular interest is the application of state-of-the-art genome-based technologies and human models of disease system to identify novel targets for intervention against disease or that predict risk of disease.

She is a recognized world expert in malaria immunology, vaccinology, and omic-based approaches for therapeutic and diagnostic development. She has been honoured as a Fellow of the International Society for Vaccines (2017) and a Fellow of the Australian Society of Parasitology (2019) in recognition of her leadership and contribution to health and medical science in Australia and internationally.

Professor Doolan serves on a number of Executive Boards and Advisory Boards. Most recently, she has been elected as President of the International Society for Vaccines (2021-2023), and has been appointed to the Federal Government's Australian Medical Research Advisory Board (AMRAB; 2021-2026) to provide specialist insights into Australia's medical research and innovation priorities.

Overview

Professor Waldemar Vollmer is a microbiologist working on the structure and biogenesis of the bacterial cell wall in various model bacteria and a range of pathogenic and environmental bacteria. He is particularly interested in how bacteria enlarge their cell wall when they grow and divide, and how antibiotics inhibit cell wall synthesis to kill bacteria. Antimicrobial resistance (AMR) is a global problem that is predicted to claim 10 million lives annually by the year 2050 if no new antibiotics are developed. Currently the pipeline of antibiotic development is almost empty and mostly limited to slightly modified versions to existing antibiotics. Professor Vollmer addresses the problem of AMR by generating tailored assays for the development of novel antibiotics that target AMR bacteria.

Collaborations: Professor Vollmer collaborates world-wide with more than 50 researchers at top national and international institutions on cell wall topics in over 30 different bacteria. These topics include: structure and composition of the cell wall and its role in maintaining cell morphology; molecular mechanisms of cell envelope biogenesis; role of new cell wall modifying enzymes in the interaction of pathogenic bacteria with components of the immune system; mechanisms of antibiotic resistance and targeting of cell wall biogenesis by new antibiotics.

Funding and Publications: Professor Vollmer has been awarded more than $15 million funding from research councils and charities in Germany, UK, Europe and USA. He has published more than 200 articles in international journals and has been recognised as a Highly Cited Researcher in Microbiology.

Honours and Awards: Professor Vollmer has been elected to Fellow of the American Academy of Microbiology (2014) and European Academy of Microbiology (2018). He received the annual Academic Distinction Awards from the Vice Chancellor of Newcastle University (2014), has been awarded a Distinguished Scientist Visiting Scholarships at Ben-Gurion University of the Negev (Israel, 2012) and a Visiting Professorship at the University of Cagliari (Italy, 2015), and won a Wellcome Trust Senior Investigator Award (2014). He has co-organised the 2018 Gordon Conference (GRC) "Bacterial Cell Surfaces" (Mt Snow, USA) and the 2016 EMBO Workshop "Bacterial Cell Division: Orchestrating the Ring Cycle" (Prague, Czech Republic).

Short Biography: Prof Waldemar Vollmer has studied chemistry at the University of Applied Sciences in Reutlingen (Germany) and University of Basel (Switzerland). In 1998 he obtained a PhD degree (Dr.rer.nat.) from the University of Tübingen (Germany) for his work on cell wall synthesis in the model bacterium Escherichia coli undertaken at the Max Planck Institute for Developmental Biology. During his postdoctoral studies at the Rockefeller University (New York, USA) he discovered novel cell wall enzymes that are crucial for the virulence of the pathogenic bacterium Streptococcus pneumoiae. In 2003 he was appointed Assistant Professor at the University of Tübingen and moved 2007 to the Centre for Bacterial Cell Biology at Newcastle University (UK), where he worked as Professor of Bacterial Biochemistry on various bacterial cell wall topics in a range of different bacteria. Since April 2023 he is Professorial Research Fellow and Group Leader at the Centre for Superbug Solutions, Institute for Molecular Bioscience (IMB) at the University of Queensland.

Brian Forde is a fellow in microbial bioinformatics and Advance Queensland Industry Research Fellow at the University of Queensland (UQ) Centre for Clinical Research (CCR). Brian was awarded a PhD from University College Cork, Ireland, in 2013 and developed his interest in bacterial genomics as a postdoctoral fellow at the UQ School of Chemistry and Molecular Biosciences (SCMB). Currently, his work is primarily focused on clinical microbial genomics, including: the evolution of antibiotic resistance, genomic epidemiology, genomic surveillance of Infectious Diseases and translating genomic research into clinical practice. Since 2017 he has been part of a multidisciplinary team, including researchers, infectious diseases clinicians and infection control professionals, leading the introduction of WGS to investigate hospital-acquired infection in Queensland (https://www.queenslandgenomics.org). In 2020, Brian was awarded Advance Queensland Industry Research Fellowship to explore the application of Artificial Intelligence to genomic surveillance and transmission dynamics.